EnzBond is an innovative British start-up developed within Oxford University by the research team Dr. Alina Rakhimova, Dr. Robert Simion, Lachlan Mackinnon and Prof. Steve Davies. EnzBond has changed the current understanding of the enzyme evolution process and made a breakthrough in biotechnology of enzyme treatment. The technology allows accelerated optimisation of biocatalysts used for the production of small molecules by predicting enzyme activity with high accuracy and at speeds faster than alternative methods. EnzBond's technology is only mechanism dependent, meaning that it can be applied to any enzyme notwithstanding sequence, structure or catalytic characteristics. With penetrate enzyme design technology it became possible to improve enzymes used in the pipeline, discover and optimise enzymes that could be applied to the processes and create a brand new custom enzyme for drug production and treatment purposes of such diseases, as for example, Gaucher disease, Fabry disease, MPS I, MPS II (Hunter syndrome), MPS VI, Pompe disease etc.